Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam ...

Employers explore glucagon-like peptide-1 (GLP-1) therapies' impact on health benefits, showcasing accountability and ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

The company hopes to stand out with Diabegone, a diabetes treatment that lasts longer than competing drugs from companies ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...